Systemic sclerosis & Raynaud's
Identification of serum exosome proteins in systemic sclerosis with interstitial lung disease by aptamer proteomics
Authors' conclusion
Aptamer proteomic analysis of circulating exosomes from patients with Diffuse SSc with and without SSc-ILD identified several biologically plausible biomarkers that may be of value to differentiate these two SSc clinical subsets.
Study context
- Population
- Patients with dcSSc with or without SSc-ILD; serum exosomes from two cohorts (first cohort: 15 without and 14 with SSc-ILD; second cohort: 12 with and 12 without SSc-ILD)two cohorts
- Comparison
- Diffuse Systemic Sclerosis (SSc) with SSc-ILD vs diffuse SSc without SSc-ILD
- Outcome
- Serum exosome proteins differentially elevated or reduced (p < 0.05 |FC|>1.2) between the two SSc clinical subsets
Methodological detailsaptamer-based proteomics (SOMAscan), discovery and validation cohorts, Validation of first-cohort proteomics results performed with the second cohort
- Aptamer-based proteomics (SOMAscan)
- Discovery and validation cohorts
- Validation of first-cohort proteomics results performed with the second cohort
Main finding
As reported in the abstract
Differentially expressed serum exosome proteins, SSc with vs without SSc-ILD
Proteins quantified
1,305
Proteins increased in SSc with SSc-ILD
29
Proteins decreased in SSc with SSc-ILD
9
Further findings
Biological pathways and correlation with DLCO
- Most increased proteins converged around enhanced inflammatory responses, immune cell activation, cell death and abnormal vascular functions
- Several displayed a highly significant correlation with CO diffusion capacity levels
Original publication
Identification of serum exosome proteins in systemic sclerosis with interstitial lung disease by aptamer proteomics. Arthritis Res Ther. Published 10 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →